Life Science Investing Traws Pharma Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025 18 August
Life Science Investing Traws Pharma Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025 18 August
Life Science Investing Traws Pharma Reports Second Quarter 2025 Results and Business Highlights 14 August
